Disoproxil fumarate, lamivudine and efavirenz tri-combination compound mini-pill tablet and preparation method thereof

A technology of tenofovir and lamivudine, which is applied in the field of pharmaceutical preparations, can solve problems such as poor compressibility, poor plasticity of pellets, and unsuitable varieties, and achieve the goal of reducing the amount of excipients, good formability, and ensuring stability Effect

Active Publication Date: 2014-07-09
ANHUI BIOCHEM BIO PHARMA
View PDF5 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

CN101252920A discloses dry granulation about tenofovir DF, emtricitabine and efavirenz triple compound, thinks that tenofovir DF and efavirenz are incompatible with the indicated active agent, both Tenofovir DF is very unstable and rapidly degrades in stability studies due to exposure
However, because the composition, particle size, density and fluidity of powders and granules are far from those of drug-containing pellets, it is impossible to protect the uniformity of mixing in the process of industrial mass production. Due to the vibration of the machine hopper, the ingredients will also be seriously stratified, resulting in the uncontrollable content of each ingredient in the compoun

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] (a) preparation of tenofovir DF coated pellets

[0037] Tenofovir DF

30g

microcrystalline cellulose

6g

lactose

2g

Croscarmellose Sodium

2.5g

2% aqueous solution of povidone K30

Q.S.

Commercially available hydroxypropyl methylcellulose coating solution

Q.S.

100 pieces

[0038] Preparation method: Weigh the prescribed amount of raw materials and auxiliary materials, mix them evenly, use 2% aqueous solution of povidone K30 as a binder to make soft materials, extrude and spheronize to prepare tenofovir DF drug-containing pellet cores, and sieve 30-40 mesh ready to use. Take the above-mentioned drug-containing pellet cores in a fluidized bed, prepare a commercially available finished hydroxypropyl methylcellulose coating solution and coat the isolation coat, and the weight of the coating will increase by about 6%, to prepare tenofovir DF coated pellets.

[0039] (b) preparation of lamivu...

Embodiment 2

[0047] (a) preparation of tenofovir DF coated pellets

[0048] Tenofovir DF

30g

microcrystalline cellulose

8g

Croscarmellose Sodium

2.5g

[0049] 2% aqueous solution of povidone K30

Q.S.

Commercially available hydroxypropyl methylcellulose coating solution

Q.S.

100 pieces

[0050] Preparation method: Weigh the prescription amount of raw materials and auxiliary materials, mix them evenly, use 2% aqueous solution of povidone K30 as the adhesive to make soft materials, extrude and spheronize to prepare tenofovir DF drug-containing pellet cores, and sieve 30-40 mesh ready to use. Take the above-mentioned drug-containing pellet cores in a fluidized bed, prepare a commercially available finished hydroxypropyl methylcellulose coating solution and coat an isolation coat, and the weight of the coating increases by about 6%, to prepare tenofovir DF coated pellets.

[0051] (b) preparation of lamivudi...

Embodiment 3

[0059] (a) preparation of tenofovir DF coated pellets

[0060] Tenofovir DF

30g

microcrystalline cellulose

6g

lactose

2g

Croscarmellose Sodium

2.5g

2% aqueous solution of povidone K30

Q.S.

Commercially available hydroxypropyl methylcellulose coating solution

Q.S.

100 pieces

[0061] Preparation method: Weigh the prescription amount of raw materials and auxiliary materials, mix them evenly, use 2% aqueous solution of povidone K30 as the adhesive to make soft materials, extrude and spheronize to prepare tenofovir DF drug-containing pellet cores, and sieve 30-40 mesh ready to use. Take the above-mentioned drug-containing pill core in a centrifugal granulation coating machine, prepare a commercially available finished product hydroxypropyl methylcellulose coating solution and coat an isolation coat, and the weight gain of the coating is about 6%, to prepare tenofovir DF coated pellets .

[00...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention discloses a tri-combination compound mini-pill tablet co-prepared by disoproxil fumarate DF coated mini-pills, lamivudine coated mini-pills and efavirenz mini-pills and a preparation method thereof. The invention solves the problems that effective component degradation and dissolution delaying phenomena are generated due to interaction among the tri-combination compound components, tabletting is not facilitated during preparation and patient swallowing is not facilitated; and the single-layer tablet having the three component drugs without mutual contact is prepared by a mini-pill tabletting method, so as to obtain good stability and fast dissolving rate.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to a triple compound pellet of tenofovir DF, lamivudine and efavirenz and a preparation method thereof. Background technique [0002] The present invention relates to the treatment of viral infections using the known antiviral compounds tenofovir DF (disoproxilfumarate, also known as TDF, trade name Viread), lamivudine (trade name Epivir) and efavirenz (trade name Sustiva) , especially HIV-infected products. [0003] HIV efficacy has been demonstrated to be ideal with tenofovir DF, lamivudine, and efavirenz. However, producing a commercially viable triple product may require that the final product be bioequivalent to the commercial products Viread, Epivir, Sustiva, and that the tablet be of an appropriate size for patients to swallow easily. [0004] Regarding the tenofovir DF, lamivudine and efavirenz triple compound pellets described in the present invention, there is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/675A61K31/536A61K31/513A61K9/20A61P31/12A61P31/18
Inventor 邢怀阳沈蔡月
Owner ANHUI BIOCHEM BIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap